Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
ceftizoxime
Synonyms :
ceftizoxime, Ceftizoxima, Ceftizoximum
Class :
Third-generation cephalosporin, Oxyimino-beta-lactam
Brand Name :
ceftizoxime
Synonyms :
ceftizoxime, Ceftizoxima, Ceftizoximum
Class :
Third-generation cephalosporin, Oxyimino-beta-lactam
Dosage Forms & StrengthsÂ
Injectable, powder, lyophilized, for solutionÂ
1 gÂ
2 gÂ
It is an antibacterial used to fight bacteria in our body that causes infections
The usual dose for the treatment of bacteremia is 1 to 4 g via Intravenous or Intramuscular administration twice or thrice a day for up to 14 days. The duration of the treatment depends on the severity and the nature of the infections
If the infection is severe, the dose can be increased up to 12 g per day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose of ceftizoxime for the treatment of cystitis is 500 mg via IM or IV twice a day for a duration of up to 3 to 7 days
Dose Adjustments
Renal Dose Adjustmen
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of urinary tract infection is 1 to 2 g via Intravenous or Intramuscular administration two or three times a day
Dose Adjustments
Renal Dose Adjustmen
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of skin or soft tissue infection is 1 to 2 g via Intravenous or Intramuscular administration two or three times a day for up to 7 or 10 days or till acute inflammation subsides
The duration of the treatment depends on the severity and the nature of the infections
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of pyelonephritis is 1 to 2 g via Intravenous or Intramuscular administration two or three times a day for up to 14 days
The duration of the treatment depends on the severity and the nature of the infections
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of pneumonia is 1 to 4 g via Intravenous or Intramuscular administration two or four times a day for up to 7 or 21 days
The duration of the treatment depends on the severity and the nature of the infections.
If the infection is severe, the dose can be increased up to 12 g per day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
In-patients with the pelvic inflammatory disease will receive 2 g IV three times a day after improvement, which makes the way for the appropriate antibiotic therapy via oral administration that should continue for 14 days
1 g via IM is administered in outpatient settings, which is followed by doxycycline oral for 14 days
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of epiglottitis is 1 to 4 g via Intravenous or Intramuscular administration twice or thrice a day for up to 7 or 14 days. The duration of the treatment depends on the severity and the nature of the infections
If the infection is severe, the dose can be increased up to 12 g per day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of osteomyelitis is 1 to 2 g via Intravenous or Intramuscular administration three or two times a day for up to 4 or 6 weeks. The duration of the treatment depends on the severity and the nature of the infections
If the infection is severe, the dose can be increased up to 12 g per day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of meningitis is 1 to 3 g via Intravenous or Intramuscular administration two or four times a day for up to 10-14 days. The duration of the treatment depends on the severity and the nature of the infections
If the infection is severe, the dose can be increased up to 12 g per day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of joint infection is 1 to 4 g via Intravenous or Intramuscular administration twice or thrice a day for up to 3 or 4 weeks. The duration of the treatment depends on the severity and the nature of the infections
In the case of prosthetic joint infection, therapy is prolonged for up to 6 weeks
If the infection is severe, the dose can be increased up to 12 g per day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose for the treatment of intraabdominal infection is 1 to 4 g via Intravenous or Intramuscular administration twice or thrice a day for up to 7 or 14 days. The duration of the treatment depends on the severity and the nature of the infections
If the infection is severe, the dose can be increased up to 12 g per day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
The usual dose 1 g IM or IV thrice a day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the usual dose of ceftizoxime depends on the CrCl. If the CrCl is below 5 mL/min, then 0.25-0.5 g a day or 0.5-1 g via IV or IM in 2 days after undergoing dialysis. Loading dose is standard in renal insufficiency, which is 0.5-1 g. 0.25 -1g twice a day if CrCl falls between 5 and 49 mL/min and 0.5 – 1.5 g thrice a day if CrCl is between 50 and 79 mL/min
Injectable, powder, lyophilized, for solutionÂ
1 gÂ
2 gÂ
In children who are below six months or equal, 50 mg/kg is given via IV three or four times a day
Refer to the adult dosingÂ
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
cephalosporins increase the effect of anticoagulation of vitamin K antagonists
cephalosporins increase the effect of anticoagulation of vitamin K antagonists
cephalosporins increase the effect of anticoagulation of vitamin K antagonists
cephalosporins increase the effect of anticoagulation of vitamin K antagonists
cephalosporins increase the effect of anticoagulation of vitamin K antagonists
they increase the effect of nephrotoxicity of aminoglycosides
neomycin/polymyxin B/bacitracin topical
they increase the effect of nephrotoxicity of aminoglycosides
they increase the effect of nephrotoxicity of aminoglycosides
they increase the effect of nephrotoxicity of aminoglycosides
they increase the effect of nephrotoxicity of aminoglycosides
ceftizoxime has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When ceftizoxime is used together with ouabain, this leads to reduction in ceftizoxime excretion
When cefmenoxime is used together with ceftizoxime, this leads to enhanced risk or seriousness of nephrotoxicity
When ceftizoxime is used together with proglumetacin, this leads to enhanced risk or seriousness of nephrotoxicity
tinidazole excretion rate is decreased when ceftizoxime is used in combination, which leads to elevated serum level concentrations
When ceftizoxime is used together with benoxaprofen, this leads to enhanced risk or seriousness of nephrotoxicity
ceftizoxime leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
ceftizoxime leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
ceftizoxime leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
ceftizoxime leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When ceftizoxime is used together with difenpiramide, this leads to enhanced risk or seriousness of nephrotoxicity
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
ceftizoxime may decrease the excretion rate of almasilate, leading to higher serum levels
ceftizoxime, when used in combination with aceclofenac, there is an increased risk of nephrotoxicity
the aclidinium excretion rate is decreased when ceftizoxime is used in combination
tramadol excretion rate is decreased when ceftizoxime is used in combination, which leads to elevated serum level concentrations
may have a decrease in excretion when combined with ceftizoxime
ceftizoxime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Actions and Spectrum:Â
Actions:Â
Third-generation cephalosporin ceftizoxime has a broad spectrum of antimicrobial activity. It is an antibacterial and antibiotic that is used to stabilize the enzymes, which are hydrolytic when secreted by bacteria.Â
Spectrum:Â
Third-generation cephalosporin ceftizoxime has a broad spectrum of antimicrobial activity. It is an antibacterial and antibiotic that is used to stabilize the enzymes, which are hydrolytic when secreted by bacteria. ceftizoxime is an antibacterial drug used in the treatment of various bacterial infections such as cystitis, meningitis, urinary tract and respiratory tract infections, and gonorrhea.Â
Frequency not definedÂ
NumbnessÂ
CellulitisÂ
Elevated AST, ALT and alkaline phosphataseÂ
VaginitisÂ
PainÂ
IndurationÂ
Transient eosinophiliaÂ
AnemiaÂ
PhlebitisÂ
TendernessÂ
LeucopeniaÂ
DiarrheaÂ
NauseaÂ
Pseudomembranous colitisÂ
ThrombocytopeniaÂ
NeutropeniaÂ
AnaphylaxisÂ
Elevated BUN and creatinineÂ
VomitingÂ
Black Box Warning:Â
None
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration: BÂ
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
Third-generation cephalosporin ceftizoxime has a broad spectrum of antimicrobial activity. It is an antibacterial and antibiotic that is used to stabilize the enzymes, which are hydrolytic when secreted by bacteria.Â
Pharmacodynamics:Â
The activity of ceftizoxime in the body is via binding to penicillin binding proteins, which shows their inhibition action in the final step of transpeptidation pf synthesis of peptidoglycan present in the cell wall of bacteria, thereby avoiding the biosynthesis and disturbing the assembling properties in the cell wall and leads to lysis of bacterial cell.Â
Pharmacokinetics:Â
AbsorptionÂ
The time to achieve peak effect is 1 hour.Â
DistributionÂ
Protein-bound is 30%Â
It is widely distributed.Â
MetabolismÂ
Limited data is available.Â
Elimination and ExcretionÂ
The half-life is 1.7 hour.Â
The unchanged drug is excreted in urine within a day.Â
Administration:Â
The usual dose for the treatment of various bacterial infections administered via is Intravenous or Intramuscular, and the duration of the treatment depends on the severity and the nature of the infections. In case of severe infections, the dose may be increased.Â
Patient information leafletÂ
Generic Name: ceftizoximeÂ
Pronounced: sef-TI-zox-eemÂ
Why do we use ceftizoxime?Â
ceftizoxime is an antibacterial drug used in the treatment of various bacterial infections such as cystitis, meningitis, urinary tract and respiratory tract infections, and gonorrhea.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
